A consensus statement on spinal muscular atrophy management in Saudi Arabia in the context of COVID-19

References

1. ↵
   1. Sohrabi C,
   2. Alsafi Z,
   3. O’Neill N,
   4. Khan M,
   5. Kerwan A,
   6. Al-Jabir A,
   7. et al.

   (2020) World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 76, 71–76.
2. ↵
   1. Saudi center for disease prevention and control

   Coronavirus 19 (COVID-19) Guidelines. , March 2020: V1.2. Available at: https://covid19.cdc.gov.sa/wp-content/uploads/2020/03/Coronavirus-Disease-2019-Guidelines-v1.2.pdf.pdf. Cited May 10, 2020.
3. ↵
   1. Hu Z,
   2. Song C,
   3. Xu C,
   4. Jin G,
   5. Chen Y,
   6. Xu X,
   7. et al.

   (2020) Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 63, 706–711.
4. ↵
   1. Betsch C,
   2. Wieler LH,
   3. Habersaat K,
   4. group C

   (2020) Monitoring behavioural insights related to COVID-19. Lancet 395, 1255–1256.
5. ↵
   1. Barry M,
   2. Gh L,
   3. Alsharidi A,
   4. Alanazi A,
   5. Alshahrani F,
   6. Alotaibi NH,
   7. et al.

   (2020) Coronavirus Disease 2019 (COVID-19) Pandemic in the Kingdom of Saudi Arabia: Mitigation Measures and Hospitals Preparedness. J Nat Sci Med.
6. ↵
   (2020) Coronavirus Disease 2019 in Children — United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 69, 422–426.
7. ↵
   1. Veerapandiyan A,
   2. Connolly AM,
   3. Finkel RS,
   4. Arya K,
   5. Mathews KD,
   6. Smith EC,
   7. et al.

   (2020) Spinal muscular atrophy care in the COVID-19 pandemic era. Muscle Nerve doi:10.1002/mus.26903.
8. ↵
   1. Guidon AC,
   2. Amato AA

   (2020) COVID-19 and neuromuscular disorders. Neurology.
9. ↵
   1. Groups at Higher Risk for Severe Illness. the Centers for Disease Control and Prevention (CDC)

   , https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html.
10. ↵
    1. Dangouloff T,
    2. Servais L

    (2019) Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. Ther Clin Risk Manag 15, 1153–1161.
11. ↵
    1. Dietz L,
    2. Horve PF,
    3. Coil DA,
    4. Fretz M,
    5. Eisen JA,
    6. Van Den Wymelenberg K

    (2020) 2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission. mSystems 5, e00245–20.
12. ↵
    Association of British Neurologists Guidance on COVID-19 for people with neurological conditions, their doctors and carers Prepared by The ABN Executive in association with subspecialist Advisory Groups. . Version 3, 22 March 2020. https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Neurology_COVID-19_Guidance_22.3.20.pdf.
13. ↵
    1. Dong Y,
    2. Mo X,
    3. Hu Y,
    4. Qi X,
    5. Jiang F,
    6. Jiang Z,
    7. et al.

    (2020) Epidemiology of COVID-19 Among Children in China. Pediatrics 145, e20200702.
14. ↵
    1. Ludvigsson JF

    (2020) Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 109, 1088–1095.
15. ↵
    1. Schroth MK

    (2009) Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics 123, Suppl 4, S245–S249.
16. ↵
    1. Boccia S,
    2. Ricciardi W,
    3. Ioannidis JPA

    (2020) What Other Countries Can Learn From Italy During the COVID-19 Pandemic. JAMA Intern Med.
17. ↵
    1. Randelli PS,
    2. Compagnoni R

    (2020) Management of orthopaedic and traumatology patients during the Coronavirus disease (COVID-19) pandemic in northern Italy. Knee Surg Sports Traumatol Arthrosc, 1–7.
18. ↵
    1. Bansal P,
    2. Bingemann TA,
    3. Greenhawt M,
    4. Mosnaim G,
    5. Nanda A,
    6. Oppenheimer J,
    7. et al.

    (2020) Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist. J Allergy Clin Immunol Pract.
19. ↵
    1. UK Government, Department of Health and Social Care

    COVID-19: guidance for young people on shielding and protecting people most likely to become unwell if they catch coronavirus. . Available at: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/withdrawn-covid-19-guidance-for-young-people-on-shielding-and-protecting-people-most-likely-to-become-unwell-if-they-catch-coronavirus.
20. ↵
    1. Burke JF,
    2. Chan AK,
    3. Mummaneni V,
    4. Chou D,
    5. Lobo EP,
    6. Berger MS,
    7. et al.

    (2020) Letter: The Coronavirus Disease 2019 Global Pandemic: A Neurosurgical Treatment Algorithm. Neurosurgery, ; Available from: https://doi.org/10.1093/neuros/nyaa116.
21. ↵
    1. Hick JL,
    2. Hanfling D,
    3. Wynia MK,
    4. Pavia AT

    , eds (2020) Duty to Plan: Health Care, Crisis Standards of Care, and Novel Coronavirus SARS-CoV-2. NAM Perspectives. Discussion paper (National Academy of Medicine, Washington (DC)) . From: https://nam.edu/duty-to-plan-health-care-crisis-standards-of-care-and-novel-coronavirus-sars-cov-2/.
22. ↵
    1. Groen EJN,
    2. Talbot K,
    3. Gillingwater TH

    (2018) Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol 14, 214–224.
23. ↵
    1. Farrar MA,
    2. Park SB,
    3. Vucic S,
    4. Carey KA,
    5. Turner BJ,
    6. Gillingwater TH,
    7. et al.

    (2017) Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 81, 355–368.
24. ↵
    1. Saudi center for disease prevention and control

    (2020) Coronavirus 19 (COVID-19) Guidelines. : V1.2. [Cited 14 May 2020] Available at: https://covid19.cdc.gov.sa/wp-content/uploads/2020/03/Coronavirus-Disease-2019-Guidelines-v1.2.pdf.pdf.
25. ↵
    1. D’Amico RS,
    2. Baum G,
    3. Serulle Y,
    4. Silva D,
    5. Smith ML,
    6. Wallack RA,
    7. et al.

    (2020) A Roadmap to Reopening a Neurosurgical Practice in the Age of COVID-19. World Neurosurg 139, 289–293.
26. ↵
    Outpatient and Ambulatory Care Settings: Responding to Community Transmission of COVID-19 in the United States. The Centers for Disease Control and Prevention (CDC), . Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/ambulatory-care-settings.html.
27. ↵
    1. Fahed M,
    2. Barron GC,
    3. Steffens DC

    (2020) Ethical and Logistical Considerations of Caring for Older Adults on Inpatient Psychiatry During the COVID-19 Pandemic. Am J Geriatr Psychiatry, ; Available from: http://www.sciencedirect.com/science/article/pii/S1064748120303286.
28. ↵
    1. Fegert JM,
    2. Vitiello B,
    3. Plener PL,
    4. Clemens V

    (2020) Challenges and burden of the Coronavirus 2019 (COVID-19) pandemic for child and adolescent mental health: a narrative review to highlight clinical and research needs in the acute phase and the long return to normality. Child Adolesc Psychiatry Ment Health 14, 20.
29. ↵
    Stress and Coping. The Centers for Disease Control and Prevention (CDC), . [Cited 14 May, 2020] Available at: https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/managing-stress-anxiety.html.
30. ↵
    1. Schorling DC,
    2. Pechmann A,
    3. Kirschner J

    (2020) Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. J Neuromuscul Dis 7, 1–13.
31. ↵
    1. Finkel RS,
    2. Mercuri E,
    3. Darras BT,
    4. Connolly AM,
    5. Kuntz NL,
    6. Kirschner J,
    7. et al.

    (2017) Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 377, 1723–1732.
32. ↵
    1. Mercuri E,
    2. Darras BT,
    3. Chiriboga CA,
    4. Day JW,
    5. Campbell C,
    6. Connolly AM,
    7. et al.

    (2018) Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med 378, 625–635.
33. ↵
    1. U.S. Food & Drug Administration

    Spinraza (nusinersen) Injection. . [Cited 14 May, 2020] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209531s003s004lbl.pdf.
34. ↵
    1. US Food & Drug Administration

    Zolgensma (onasemnogene abeparvovec-xioi). . [Accessed May 14, 2020] https://www.fda.gov/media/126109/download.
35. ↵
    1. Youssef J,
    2. Novosad SA,
    3. Winthrop KL

    (2016) Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am 42, 157–176.
36. ↵
    1. Wee LE,
    2. Fua TP,
    3. Chua YY,
    4. Ho AFW,
    5. Sim XYJ,
    6. Conceicao EP,
    7. et al.

    (2020) Containing COVID-19 in the Emergency Department: The Role of Improved Case Detection and Segregation of Suspect Cases. Acad Emerg Med. 27, 379–387.
37. ↵
    1. Dinesen B,
    2. Nonnecke B,
    3. Lindeman D,
    4. Toft E,
    5. Kidholm K,
    6. Jethwani K,
    7. et al.

    (2016) Personalized Telehealth in the Future: A Global Research Agenda. J Med Internet Res 18, e53–e53.
38. ↵
    1. Baioni MTC,
    2. Ambiel CR

    (2010) Spinal muscular atrophy: diagnosis, treatment and future prospects. J Pediatr (Rio J) 86, 261–270.
39. ↵
    1. Paganoni S,
    2. Nicholson K,
    3. Leigh F,
    4. Swoboda K,
    5. Chad D,
    6. Drake K,
    7. et al.

    (2017) Developing multidisciplinary clinics for neuromuscular care and research. Muscle Nerve 56, 848–858.
40. ↵
    1. Esquinas AM

    1. Racca F,
    2. Robba C,
    3. Dusio MP

    (2016) in Noninvasive Mechanical Ventilation in Patients with Neuromuscular Disease BT - Noninvasive Mechanical Ventilation and Difficult Weaning in Critical Care: Key Topics and Practical Approaches, ed Esquinas AM (Springer International Publishing, Cham), 247–58.